@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAchhUlX8-bXqvxGre5FBYNMhxHFh0QE12TJtQsC-loOU> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAchhUlX8-bXqvxGre5FBYNMhxHFh0QE12TJtQsC-loOU#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix scomp: <http://resource.belframework.org/belframework/20131211/namespace/selventa-named-complexes/> .
@prefix ProteinComplex: <http://amigo.geneontology.org/amigo/term/GO:0043234> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   scomp:p85%2Fp110%20PI3Kinase%20Complex a ProteinComplex: .
  sub:_1 geneProductOf: hgnc:6018 ;
    a Protein: .
  sub:_2 hasAgent: scomp:p85%2Fp110%20PI3Kinase%20Complex ;
    a go:0016301 .
  sub:_3 occursIn: obo:CLO_0009251 , species:9606 ;
    rdf:object sub:_2 ;
    rdf:predicate belv:increases ;
    rdf:subject sub:_1 ;
    a rdf:Statement .
  sub:assertion rdfs:label "p(HGNC:IL6) -> kin(complex(SCOMP:\"p85/p110 PI3Kinase Complex\"))" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "20131211" .
  sub:_4 prov:value "IL-6 treatment led to activation of the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3'-kinase (PI3K) pathways. Inhibition of MAPK or PI3K activity reversed IL-6- and oncostatin M-stimulated migration. For transient transfections, plasmids were introduced into the cells using Superfect transfection reagent (Qiagen). A HA-tagged MAPK (Erk2) construct (kindly provided by M. El-Shemerly and Y. Nagamine; Friedrich Miescher Institute, Basel, Switzerland) was cotransfected with a DN EGF receptor construct lacking 533 COOH-terminal amino acids MAPK kinase inhibitors PD98059 (20 uM; New England Biolabs) or UO126 (50 uM; Promega, Madison, WI PD98059, which is known to specifically inhibit the ERK-activating kinase MEK1, has been widely used to assess the effects of dampening ERK activation. MEK inhibitor UO126 (Promega, MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2)." ;
    prov:wasQuotedFrom pubmed:11196191 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:11196191 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:31:39.817+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}